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Abstract 
Background: Vancomycin may be inferior to β-lactams for the empiric treatment of methicillin-susceptible Staphy-
lococcus aureus (MSSA) bacteremia. We compared empiric β-lactams to vancomycin to assess clinical outcomes in 
patients with MSSA bacteremia.
Methods: We conducted a retrospective cohort study of adult inpatients with their first episode of MSSA bacteremia 
at two tertiary care hospitals in Vancouver, Canada, between 2007 and 2014. Exposure was either empiric β-lactam 
with or without vancomycin or vancomycin monotherapy. All patients received definitive treatment with cloxacillin or 
cefazolin. The primary outcome was 28-day mortality. Secondary outcomes were 90-day mortality, duration of bacte-
remia, and hospital length-of-stay. Outcomes were adjusted using multivariable logistic regression.
Results: Of 669 patients identified, 255 met inclusion criteria (β-lactam = 131, vancomycin = 124). Overall 28-day 
mortality was 7.06 % (n = 18). There were more cases of infective endocarditis in the β-lactam than in the vancomycin 
group [24 (18.3 %) vs 12 (9.7 %), p = 0.05]. Adjusted mortality at 28 days was similar between the two groups (OR 0.85; 
95 % CI 0.27–2.67). The duration of bacteremia was longer in the vancomycin group (97.1 vs 70.7 h, p = 0.007). Transi-
tion to cloxacillin or cefazolin occurred within a median of 68.3 h in the vancomycin group.
Conclusions: Empiric β-lactams was associated with earlier clearance of bacteremia by a median of 1 day compared 
to vancomycin. Future prospective studies are needed to confirm our findings.
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Background
Staphylococcus aureus is the leading cause of bactere-
mia and carries a mortality of 20–30  % in the twenty-
first century [1, 2]. Empiric vancomycin is commonly 
prescribed when S. aureus is isolated from a blood cul-
ture but antimicrobial susceptibilities are not yet known, 
because up to 50–60  % of bloodstream isolates are 
methicillin-resistant S. aureus (MRSA) at some centres 
[3–8]. However, vancomycin is inferior to semi-synthetic 
anti-Staphylococcal penicillins (e.g., cloxacillin) and 
first generation cephalosporins (e.g., cefazolin) for the 
definitive treatment of methicillin-susceptible S. aureus 
(MSSA) bacteremia [9–11]. Cloxacillin and cefazolin 
are equally efficacious in treating MSSA bacteremia and 
are the optimal agents against MSSA [10]. Vancomycin 
is associated with higher rates of infection-related mor-
tality, re-infection and bacteriologic failure compared 
to cloxacillin or cefazolin in the definitive treatment of 
MSSA bacteremia [9, 12–15]. Whether vancomycin is 
inferior to β-lactams for empiric therapy remains to be 
fully elucidated. Early studies suggested that empiric van-
comycin was associated with worse outcomes compared 
to empiric β-lactam therapy [3, 16, 17], but more recent 
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data did not demonstrate any differences [15]. Although 
controversial, some experts recommend the addition 
of a β-lactam agent to empiric therapy to provide opti-
mal coverage for MSSA in patients at the highest risk 
of morbidity and mortality from S. aureus bacteremia 
(SAB) [18]. Currently, no studies have compared empiric 
β-lactam to vancomycin in patients with MSSA bactere-
mia who are transitioned to cloxacillin or cefazolin for 
definitive therapy. We assessed if empiric β-lactam with 
or without vancomycin compared to vancomycin alone 
was associated with differences in clinical outcomes in 
patients with MSSA bacteremia who received definitive 
therapy with cloxacillin or cefazolin.
Methods
Patients
We performed a retrospective cohort study of adult 
inpatients aged 18 and older diagnosed with their first 
episode of MSSA bacteremia at two tertiary care hos-
pitals in Vancouver, Canada, between January 2007 and 
December 2014, inclusive. Both hospitals are large aca-
demic institutions (955 and 435 beds) affiliated with the 
University of British Columbia that are served by infec-
tious diseases physicians who share similar treatment 
strategies for SAB. Consecutive patients were included 
if they received definitive therapy with either cloxacillin 
or cefazolin. Patients were excluded if there was missing 
data for 28-day mortality, no empiric therapy was admin-
istered, death occurred within 24 h following diagnosis of 
bacteremia, or polymicrobial bacteremia. Patients were 
stratified based on empiric treatment with β-lactams or 
vancomycin. The β-lactam group received one or more 
of cloxacillin, cefazolin, β-lactam/β-lactamase inhibitor 
combination, a third generation cephalosporin or a car-
bapenem, with or without vancomycin. The vancomycin 
group was not exposed to any β-lactams until the start of 
definitive therapy. In both groups, other antimicrobials 
may have been prescribed during empiric and definitive 
therapy.
Definitions
Bacteremia was defined as the isolation of MSSA from 
one or more blood culture bottles. Bacteremia identified 
within 48 h of hospital admission was considered commu-
nity-onset, while bacteremia diagnosed after more than 
48  h of hospital admission was deemed hospital-onset. 
Immunocompromised state was present if any of the 
following were described: neutropenia (≤1.5  ×  109/L), 
congenital immune deficiencies, or use of immunosup-
pressants (TNF-α inhibitors, prednisone ≥10  mg/day 
or its equivalent, cancer chemotherapy, methotrexate, 
cyclophosphamide, mycophenolate mofetil, calcineu-
rin inhibitors, mTOR inhibitors, azathioprine). Definite 
infective endocarditis was diagnosed using the modi-
fied Duke criteria [19]. The source of bacteremia was 
either stated explicitly or inferred as the most likely 
source based on available clinical data and microbiologi-
cal results. Metastatic complications included infections 
that occurred distant from the presumed primary source 
such as septic emboli, mycotic aneurysms, osteoarticular 
infections, and distant abscesses. Surgical source con-
trol included only procedures performed in the operat-
ing theatre. Empiric therapy began with the first dose of 
empiric antibiotics and ended with the start of definitive 
therapy. Definitive therapy began when antimicrobial 
susceptibilities were released and one of the following 
treatments was prescribed: (1) cloxacillin or cefazolin (2) 
discontinuation of other empiric antibiotics for patients 
already on cloxacillin or cefazolin empirically, or (3) con-
tinuation of empiric cloxacillin or cefazolin. Definitive 
therapy ended when cloxacillin or cefazolin was stopped. 
Time to receipt of antibiotics was measured from the 
time of obtaining the first positive blood culture to the 
time of the first dose of antibiotic. If a patient was already 
on antibiotics at the time of the first positive blood cul-
ture, the time to receipt of antibiotics was zero.
Outcomes
Our primary outcome was 28-day all-cause mortal-
ity. Secondary outcomes were 90-day all-cause mortal-
ity, duration of bacteremia, and hospital length-of-stay 
(LOS). Time to mortality was measured from the date of 
the first positive blood culture to the date of death. Dura-
tion of bacteremia was the time difference between the 
first positive blood culture and the first negative blood 
culture. Patients without follow-up blood cultures were 
excluded from the analysis for duration of bacteremia. 
Hospital LOS was measured from the date of the first 
positive blood culture for MSSA to the date of discharge. 
Patients who did not survive to hospital discharge were 
excluded from the hospital LOS analysis.
Data extraction
Patients with MSSA bacteremia were extracted from the 
medical microbiology laboratory information systems 
and medical records were reviewed. A single reviewer 
collected data on patient demographics and comorbidi-
ties, blood culture results and antimicrobial therapy.
Statistical analysis
Our predicted mortality difference between the β-lactam 
and vancomycin group was 15  % based on a previous 
study [17]. We estimated a sample size of 100 for each 
group to capture a 15  % difference in mortality, assum-
ing a mortality rate of 25 and 10  % in the vancomycin 
and β-lactam group respectively, with 80  % power at a 
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two-tailed alpha level of 0.05. Baseline categorical vari-
ables were described as counts and percentages, and dif-
ferences between groups were assessed with Chi square 
or Fisher’s exact tests. Continuous variables were pre-
sented as means and standard deviations, or medians 
and interquartile range. Differences between groups 
were assessed using parametric t-tests or non-para-
metric Mann–Whitney U tests, as appropriate. Logistic 
regression methods were used to model the odds ratio of 
death in the β-lactam compared to vancomycin group. 
In order to reduce the small sample size bias, Firth cor-
rection method was applied to 28- and 90-day mortality 
[20]. Linear regression model was conducted for hospital 
LOS and duration of bacteremia. The two outcomes were 
log-transformed in the analysis to improve normality of 
the distribution of residuals. All models were adjusted 
for age, age-adjusted Charlson-comorbidity index (CCI) 
[21], infectious diseases consultation, infective endo-
carditis and time to receipt of empiric antibiotics. The 
duration of bacteremia was further adjusted for surgical 
source control. All analyses were performed using the 
SAS 9.4 software.
Ethics
The study was approved by the research ethics board at 
the University of British Columbia, and received insti-
tutional approval from Vancouver Coastal Health and 
Providence Healthcare.
Results
We identified 669 patients with MSSA bacteremia 
between January 2007 and December 2014, inclusive 
(Fig.  1). We excluded 414 patients primarily because 
60.4 % did not receive cloxacillin or cefazolin for defini-
tive therapy. These patients either remained on broad-
spectrum antimicrobials or received vancomycin for 
definitive therapy due to suspected or confirmed penicil-
lin allergy. Another 22.9  % were not started on empiric 
therapy. Our cohort consisted of 66.3 % males and 74.1 % 
of patients had community-onset bacteremia (Table  1). 
Compared to the β-lactam group, patients in the van-
comycin group were older (mean age 59.4 vs 53.2 years, 
p  =  0.005), had more medical comorbidities (median 
CCI 4 vs 3, p = 0.001), and were diagnosed with a greater 
proportion of hospital-onset bacteremia (32.3 vs 19.8 %, 
p = 0.03). Infectious diseases consultation was obtained 
in most cases (69.8  %), but tended to be higher in the 
β-lactam (74.8 %) than in the vancomycin group (64.5 %).
The most common sources of bacteremia in our cohort 
were unknown (27.1  %), skin and soft tissue infections 
(18.4 %), peripheral or central venous catheters (16.5 %) 
and injection drug use (15.7  %). Infective endocarditis 
was diagnosed more frequently and surgical source con-
trol was achieved more often in the β-lactam (18.3 and 
25.2 % respectively) compared to the vancomycin group 
(9.7 and 15.3 % respectively). The prevalence of infective 
endocarditis was 14.1 %. 
In the β-lactam group, the use of multiple β-lactam 
antibiotics reflects changes made during empiric ther-
apy, but cloxacillin or cefazolin was continued until the 
start of definitive therapy. One patient in the vancomycin 
group received only a partial dose of vancomycin and was 
counted as not having received it. There was a greater 
delay in receipt of empiric antimicrobials in the vanco-
mycin group (median 20.9 vs 2  h, p  <  0.001).Transition 
to cloxacillin or cefazolin occurred within a median of 
68.3 h in the vancomycin group. Among the subgroup of 
patients who received combination therapy with β-lactam 
plus vancomycin (88/131), 3rd generation cephalospor-
ins (39.8  %) and piperacillin–tazobactam (34.1  %) were 
the most common empiric β-lactams prescribed initially 
(Table 2). Initiation of cloxacillin or cefazolin during the 
empiric period was delayed in the combination subgroup 
compared to the subgroup that received β-lactam mono-
therapy (median 23.1 vs 6.5 h, p = 0.001). The combina-
tion subgroup had a higher Pitt bacteremia score (median 
1 vs 0, p = 0.01), received more infectious diseases con-
sultations (80.7 vs 62.8  %, p  =  0.03), and experienced 
more metastatic complications (37.5 vs 16.3 %, p = 0.02) 
than the β-lactam monotherapy subgroup. Hospital LOS 
was shorter in patients who received β-lactam monother-
apy (median 14 vs 22 days, p = 0.02).
The adjusted odds ratio of death at 28 and 90  days 
between the β-lactam and vancomycin group was 0.85 
(95  % CI 0.27–2.67) and 0.88 (0.36–2.17) respectively 
(Table  3). The overall 28- and 90-day mortality was 18 
(7.06  %) and 36 (14.1  %) respectively. Among patients 
with infective endocarditis, 28- and 90-day mortality 
was 2 (8.33 %) and 3 (12.5 %) in the β-lactam group and 
Fig. 1 Patient enrollment process. MSSA methicillin-susceptible S. 
aureus, BSI bloodstream infection
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0 and 1 (8.33 %) in the vancomycin group. No mortality 
differences were observed between the two hospitals. 
The duration of bacteremia was shorter in the β-lactam 
than in the vancomycin group (median 70.7 vs 97.1  h, 
p = 0.007) with an adjusted ratio of mean of 0.77 (95 % 
CI 0.62–0.95). Hospital LOS was similar between the two 
groups with an adjusted ratio of mean of 0.86 (95  % CI 
0.66–1.10).
Table 1 Comparison of  baseline characteristics and  clinical outcomes of  patients with  methicillin-susceptible S. aureus 
bacteremia who received empiric antimicrobial therapy with β-lactams or vancomycin
Patient characteristics β-lactama (n = 131) Vancomycina (n = 124) p value
Age (mean ± standard deviation in years) 53.2 ± 16.5 59.4 ± 18.3 0.005
Males 83 (63.4) 86 (69.4) 0.31
Community-onset 105 (80.2) 84 (67.8) 0.03
Hospital-onset 26 (19.8) 40 (32.3) 0.03
HIV infection 11 (8.4) 8 (6.5) 0.55
Hepatitis C infection 29 (22.1) 28 (22.6) 0.93
Immunocompromised 14 (10.7) 10 (8.1) 0.47
Alcohol or illicit drug abuse 41 (31.3) 38 (30.6) 0.91
Intravenous drug use 29 (22.1) 29 (23.4) 0.81
Charlson comorbidity index (median with IQR) 3 (1.0–6.0) 4 (1.0–7.0) 0.001
Pitt bacteremia score (median with IQR) 1 (0–2) 1 (0–2) 0.17
Infectious diseases consultation 98 (74.8) 80 (64.5) 0.07
Source of bacteremia
 Central or peripheral line 20 (15.3) 22 (17.7) 0.62
 Skin and soft tissue 31 (23.7) 16 (12.9) 0.04
 Intravenous drug use 21 (16.0) 19 (15.3) 1.00
 Bone or joint infection 18 (13.7) 10 (8.1) 0.16
 Lung 4 (3.1) 3 (2.4) 1.00
 Other 12 (9.2) 10 (8.1) 0.83
 Unknown 25 (19.1) 44 (35.5) 0.005
Infective endocarditis 24 (18.3) 12 (9.7) 0.05
Metastatic complications 40 (30.5) 27 (21.8) 0.11
Surgical source control 33 (25.2) 19 (15.3) 0.05
Recurrent infection at 6 months 4 (3.1) 4 (3.2) 1.00
Empiric antimicrobials
 Vancomycin 88 (67.2) 123 (99.2) <0.001
 Daptomycin 2 (1.5) 0 0.50
 Linezolid 2 (1.5) 0 0.50
 Cloxacillin or cefazolin 131 (100) 0 <0.001
 3rd generation cephalosporin 40 (30.5) 0 <0.001
 Piperacillin–tazobactam 33 (25.2) 0 <0.001
 Ticarcillin–clavulanic acid 3 (2.3) 0 0.25
 Carbapenem 2 (1.5) 0 0.50
 Otherb 47 (35.9) 66 (53.2) 0.01
Blood culture time to positivity (median hours with IQR) 20 (16.5–24.9) 18.3 (15.9–23.5) 0.17
Duration of empiric therapy (median hours with IQR) 54 (42.0–69.0) 48 (29.6–75.8) 0.28
Duration of definitive therapy (median days with IQR) 31.5 (13.0–42.0) 28 (10.0–42.0) 0.17
Time to receipt of empiric therapy (median hours with IQR) 2 (0–7) 20.9 (4.2–28.3) <0.001
Time to receipt of β-lactam (median hours with IQR) 3 (0.2–16.3) 68.2 (51.5–95.4) <0.001
Time to receipt of cloxacillin or cefazolin (median hours with IQR) 21.0 (4.4–31.2) 68.3 (51.6–95.4) <0.001
Primary outcome
 28-day mortality 7 (5.3) 11 (8.9) 0.27
Page 5 of 9Wong et al. Ann Clin Microbiol Antimicrob  (2016) 15:27 
Discussion
The goal of our study was to assess if empiric β-lactams 
with or without vancomycin compared to vancomy-
cin alone was associated with differences in outcomes 
in patients with MSSA bacteremia. We found no dif-
ferences in all-cause mortality at 28 and 90  days, or 
hospital LOS between these two groups. Clearance of 
bacteremia was delayed by a median of 1 day in the van-
comycin group. However, this outcome may have been 
confounded by the earlier receipt of empiric antibiotics 
in the β-lactam group (median 2 h). When we analyzed 
a subset of patients from the vancomycin group (n = 43) 
whose median time to receipt of empiric antibiotics was 
1.97 h, the duration of bacteremia was still longer com-
pared to the β-lactam group, but just shy of statistical sig-
nificance (95.1 vs 70.7 h, p = 0.06), likely because of the 
reduced sample size. Therefore, it does not appear that 
time to receipt of empiric therapy had a major impact on 
time to clearance of bacteremia in our study. Despite the 
high prevalence of MRSA at both of our institutions (25 
and 38 %), only 67.2 % of patients in the β-lactam group 
received vancomycin empirically as well. Perhaps the 
awareness of MRSA was low among some treating clini-
cians or patients who did not receive empiric vancomycin 
were judged to be at low risk for MRSA infection.
Interestingly, the differential time delay in receipt of 
empiric antimicrobials was unexpected. Patients in the 
β-lactam group generally received antibiotics well before 
the blood culture became positive, while patients in the 
vancomycin group tended to receive antibiotics shortly 
after the blood culture turned positive. The reason for 
this observation is likely multifactorial. First, β-lactam 
patients generally had more identifiable sources of bac-
teremia (i.e. more skin and soft tissue infections). Second, 
the higher prevalence of community-onset bacteremia 
suggests these patients may have had their first medical 
contact with the emergency department where sepsis 
protocols facilitated timely administration of antibiotics.
In the β-lactam group, patients who received empiric 
β-lactam plus vancomycin had a higher Pitt bacteremia 
score, experienced more metastatic complications and 
stayed in hospital longer than those who received empiric 
β-lactam monotherapy. The greater severity of illness in 
this combination subgroup may explain the initial use 
of broad-spectrum β-lactams (ceftriaxone or pipera-
cillin–tazobactam), with subsequent de-escalation to 
cloxacillin or cefazolin during the empiric period by the 
infectious diseases consultant when S. aureus was identi-
fied in the blood culture. De-escalation occurred within a 
median of 23.1 h, which follows the time to positivity of 
the first blood culture (median 20 h). Despite differences 
in baseline characteristics and antimicrobials prescribed, 
mortality rates and time to clearance of bacteremia were 
similar between these subgroups.
Our study outcomes were similar to those reported 
in the literature. The overall 28- and 90-day mortality in 
our study was low at 18 (7.06 %) and 36 (14.1 %) respec-
tively, but is within the range of 3.6–51.7 % described in 
a meta-analysis of patients with MSSA bacteremia from 
catheter-related infections and infective endocarditis by 
Cosgrove et  al. [22]. Definite infective endocarditis was 
diagnosed in 36 (14.1 %) of our patients, which is similar 
to rates reported in previous studies [10, 14, 16, 23, 24].
The median duration of bacteremia was longer in 
the vancomycin compared to the β-lactam group (4 vs 
3 days) in our study. In a similar study by Khatib et al. [3], 
clearance of bacteremia was delayed (duration ≥3 days) 
more often in patients who received empiric vancomy-
cin (57.6  %) compared to those who received empiric 
β-lactams (37.5  %). They reported no difference in all-
cause or attributable mortality between groups.
We did not find any differences in mortality between 
treatment groups in our study. In contrast, Lodise et al. 
[17] demonstrated that empiric β-lactam was associated 
with lower infection-related mortality than with empiric 
vancomycin monotherapy (11.4 vs 39.3  %, p  =  0.005) 
IQR interquartile range
a Variables are displayed as counts and percentages in parentheses unless otherwise specified
b Other antimicrobials used during empiric and definitive therapy included rifampin, aminoglycosides, fluoroquinolones, macrolides, trimethoprim-sulfamethoxazole, 
and clindamycin
c 15 and 10 patients from the β-lactam and vancomycin group respectively were excluded from the analysis due to lack of follow-up blood cultures
d 12 and 19 patients from the β-lactam and vancomycin group respectively were excluded from the analysis due to death during hospital admission
Patient characteristics β-lactama (n = 131) Vancomycina (n = 124) p value
Secondary outcomes
 90-day mortality 14 (10.7) 22 (17.7) 0.11
 Duration of bacteremia (median hours with IQR)c 70.7 (46.9–119) 97.1 (61.6–148) 0.007
 ≥3 days 58 (50) 72 (63.2) 0.047
 Hospital length of stay (median days with IQR)d 17 (11–36) 17 (12–36.5) 0.84
Table 1 continued
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Table 2 Comparison of  baseline characteristics and  clinical outcomes of  patients with  methicillin-susceptible S. aureus 
bacteremia who received empiric combination therapy with β-lactam plus vancomycin or empiric β-lactam monotherapy
Patient characteristics β-lactam plus vancomycina  
(n = 88)
β-lactam monotherapya  
(n = 43)
p value
Age (mean ± standard deviation in years) 50.5 ± 16.4 58.9 ± 16.6 0.006
Males 53 (60.2) 30 (69.8) 0.34
Community-onset 74 (84.1) 31 (72.1) 0.16
Hospital-onset 14 (15.9) 12 (27.9) 0.16
HIV infection 9 (10.2) 2 (4.7) 0.34
Hepatitis C infection 19 (21.6) 10 (23.3) 0.83
Immunocompromised 8 (9.1) 6 (14.0) 0.39
Alcohol or illicit drug abuse 29 (33.0) 12 (27.9) 0.69
Intravenous drug use 21 (23.9) 8 (18.6) 0.65
Charlson comorbidity index (median with IQR) 2 (1–4) 3 (1–5) 0.07
Pitt bacteremia score (median with IQR) 1 (0–2) 0 (0–1) 0.01
Infectious diseases consultation 71 (80.7) 27 (62.8) 0.03
Source of bacteremia
 Central or peripheral line 12 (13.6) 8 (18.6) 0.45
 Skin and soft tissue 20 (22.7) 11 (25.6) 0.83
 Intravenous drug use 16 (18.2) 5 (11.6) 0.45
 Bone or joint infection 10 (11.4) 8 (18.6) 0.29
 Lung 2 (2.3) 2 (4.7) 0.60
 Other 9 (10.2) 3 (7.0) 0.75
 Unknown 19 (21.6) 6 (14.0) 0.35
Infective endocarditis 19 (21.6) 5 (11.6) 0.23
Metastatic complications 33 (37.5) 7 (16.3) 0.02
Surgical source control 22 (25) 11 (25.6) 1.00
Recurrent infection at 6 months 2 (2.3) 2 (4.7) 0.60
Empiric antimicrobials
 Daptomycin 0 2 (4.7) 0.11
 Linezolid 1 (1.1) 1 (2.3) 0.55
 Cloxacillin or cefazolin 88 (100) 43 (100) 1.00
 3rd generation cephalosporin 35 (39.8) 5 (11.6) 0.001
 Piperacillin–tazobactam 30 (34.1) 3 (7.0) <0.001
 Ticarcillin–clavulanic acid 2 (2.3) 1 (2.3) 1.00
 Carbapenem 1 (1.1) 1 (2.3) 0.55
 Otherb 27 (30.7) 20 (46.5) 0.08
Blood culture time to positivity (median hours with IQR) 20 (16.0–24.0) 20.7 (18–27.3) 0.07
Duration of empiric therapy (median hours with IQR) 54.1 (43.0–71.7) 51.7 (38–64.5) 0.18
Duration of definitive therapy (median days with IQR) 38 (16–43) 23 (12–40) 0.08
Time to receipt of empiric therapy (median hours with IQR) 1.91 (0–6.17) 3.42 (0.58–17.2) 0.19
Time to receipt of β-lactam (median hours with IQR) 2.88 (0.21–15.1) 3.42 (0.58–17.2) 0.87
Time to receipt of cloxacillin or cefazolin (median hours with 
IQR)
23.1 (13.0–31.7) 6.5 (1.5–22.1) 0.001
Primary outcome
 28-day mortality 5 (5.7) 2 (4.7) 1.00
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among injection drug users with predominantly right-
sided MSSA infective endocarditis. Even when patients 
were switched from vancomycin to a semi-synthetic pen-
icillin within a median of 3 days, infection-related mor-
tality remained high at 40.9  %. The overall mortality in 
Lodise’s cohort was unusually high at 22.2 % compared to 
a rate of 0–4 % described in a systematic review by Yung 
et  al. [25]. The largest study to date by McDanel et  al. 
revealed that empiric β-lactam therapy (predominantly 
piperacillin–tazobactam and ceftriaxone) compared to 
vancomycin was not associated with differences in mor-
tality in patients with MSSA bacteremia [15]. However, 
this study excluded patients who received empiric van-
comycin plus β-lactams, did not address microbiological 
cure, and evaluated empiric regimens independent of the 
definitive antimicrobial therapy prescribed.
We included a large proportion of patients who 
received empiric treatment with optimal anti-MSSA 
agents (cloxacillin or cefazolin), whereas previous obser-
vational studies have either failed to specify the β-lactam 
agents used or enrolled patients who received mostly 
broad-spectrum β-lactams. This is an important point 
because not all β-lactams have equal efficacy against 
MSSA. As demonstrated in one study, empiric cefazolin 
or cloxacillin was associated with improved short-term 
survival compared to empiric regimens containing other 
β-lactams [26]. Therefore, the ideal study is one that com-
pares a semi-synthetic anti-Staphylococcal penicillin or 
cefazolin to vancomycin.
Our study has several limitations. The reason for the 
lack of difference in the primary outcome is likely mul-
tifactorial. Because of the low event rate in both groups, 
our study was potentially underpowered to detect a sig-
nificant difference in mortality. The lower than expected 
death rate may be partly due to the exclusion of patients 
who died within 24  h of the diagnosis of SAB and of 
patients who remained on broad-spectrum β-lactams. 
This group may have represented a sicker population and 
thus, we may have selected for less critically ill patients. 
The absence of matching with respect to baseline char-
acteristics and the retrospective nature of the study may 
have also contributed to a lack of difference in the pri-
mary outcome. Obtaining subsequent blood cultures was 
often delayed, which may have led to an overestimation 
Table 3 Outcome analysis comparing empiric β-lactam versus  vancomycin, adjusted for  age, age-adjusted Charlson-
comorbidity index, infectious diseases consultation, infective endocarditis and time to receipt of empiric antibiotics
Duration of bacteremia was further adjusted for surgical source control
OR odds ratio, CI confidence interval
Outcomes Crude OR (95 % CI) p value Adjusted OR (95 % CI) p value
28-day mortality 0.60 (0.23–1.55) 0.29 0.85 (0.27–2.67) 0.78
90-day mortality 0.56 (0.28–1.15) 0.11 0.88 (0.36–2.17) 0.79
Ratio of mean (95 % CI) p value Adjusted ratio of mean (95 % CI) p value
Duration of bacteremia 0.77 (0.64–0.93) 0.01 0.77 (0.62–0.95) 0.01
Hospital length-of-stay 0.85 (0.68–1.07) 0.16 0.86 (0.66–1.10) 0.23
IQR interquartile range
a Variables are displayed as counts and percentages in parentheses unless otherwise specified
b Other antimicrobials used during empiric and definitive therapy included rifampin, aminoglycosides, fluoroquinolones, macrolides, trimethoprim-sulfamethoxazole, 
and clindamycin
c 6 and 9 patients from the β-lactam plus vancomycin and β-lactam monotherapy subgroup respectively were excluded from the analysis due to lack of follow-up 
blood cultures
d 9 and 3 patients from the β-lactam plus vancomycin and β-lactam monotherapy subgroup respectively were excluded from the analysis due to death during 
hospital admission
Patient characteristics β-lactam plus vancomycina  
(n = 88)




 90-day mortality 10 (11.4) 4 (9.3) 1.00
 Duration of bacteremia (median hours with IQR)c 71.4 (50.3–126.9) 68.5 (36.4–115.8) 0.35
 ≥3 days 41 (46.6) 17 (39.5) 0.46
 Hospital length of stay (median days with IQR)d 22 (12–44) 14 (10–22.8) 0.02
Table 2 continued
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of the duration of bacteremia. However, this effect was 
likely balanced between both groups. Data regarding 
adverse effects were not collected due to the difficulty 
of establishing drug-related events in a retrospective 
study. A randomized controlled trial would be ideal to 
address our study question because it would provide bet-
ter matching of patient baseline characteristics and con-
trol of antimicrobials prescribed, and permit prospective 
monitoring of adverse drug effects. In such a study, daily 
blood cultures would need to be collected to determine 
the exact date of clearance of bacteremia. As well, more 
accurate estimation of the expected mortality rates 
between groups would be needed when calculating the 
required sample size. Collaboration between the medical 
microbiology laboratory, infectious diseases service and 
antimicrobial stewardship team is essential to execute 
such a trial.
Until we have more concrete evidence from future 
prospective studies, the benefit of adding a β-lactam to 
empiric therapy for MSSA bacteremia remains unclear. 
Ultimately, the choice of empiric regimen will depend 
on patient factors, the prevalence of MRSA in the popu-
lation, and the ability of the microbiology laboratory to 
rapidly differentiate MSSA from MRSA.
In conclusion, empiric therapy with β-lactams was 
associated with earlier clearance of bacteremia by a 
median of 1  day compared to vancomycin, but was not 
associated with differences in all-cause mortality or hos-
pital LOS in patients with MSSA bacteremia. Our data 
should be interpreted with caution however, as major 
differences in the baseline characteristics between the 
groups may have overshadowed any potential treatment 
effect. Future prospective studies are needed to confirm 
our findings. For now, empiric treatment with vancomy-
cin is reasonable if the prevalence of MRSA is significant. 
The addition of a β-lactam agent could be considered in 
critically ill patients.
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